Pharmaceutical materials scientist wins 2012 McBain Medal
For his research in the field of colloid, polymer and interface science
Dr Vitaliy Khutoryanskiy, a reader in pharmaceutical materials at Reading’s School of Chemistry, Food and Pharmacy, has won the 2012 McBain Medal for his work in the field of colloid, polymer and interface science.
The medal, a joint award of the Royal Society of Chemistry (RSC) and the Society of Chemical Industry (SCI), will be presented to Dr Khutoryanskiy at a one-day symposium in January 2013, at which he will deliver a keynote lecture.
The main focus of Dr Khutoryanskiy’s work is developing new materials to help in the administration of drugs, the treatment of wounds, and technology to contain innovative treatments such as proteins, bacteria and living cells such as stem cells, which could all help in the fight against disease.
His research into the behaviour of water-soluble polymers in solution mixtures has resulted in a number of advances leading to the formulation of nanomaterials, soft and superabsorbent hydrogels, thin films and microcapsules.
His research team has extensively studied the ability of various pharmaceutical polymers to ‘stick’ to mucosal surfaces, such as those found in the mouth, stomach or on the surface of the eye, allowing new ways to administer drugs.
This sticking property allows drugs to be retained more easily where they are needed in the body. In the eyes, for example, conventional eye drops are quickly washed away by tears and blinking, but a ‘sticky’ dose allows more drugs to penetrate the eye, making treatments dramatically quicker and more effective.
Hydrogels are also very promising for wound care applications, where their ability to absorb large amounts of biological fluids is used to develop wound dressings that can aid the healing process, provide protection for the newly formed tissue, and be easily removed without causing a trauma.
Dr Khutoryanskiy’s group has recently developed hydrogels that have excellent potential in this area, which are in development with a range of industrial partners.
The team has also developed different approaches for the encapsulation of proteins, probiotic bacteria and living cells, potentially leading to new approaches for the development and delivery of therapeutic treatments.
Dr Khutoryanskiy said it is a great honour to win the 2012 McBain Medal, which recognises the research he and his team have been doing for the past 10 years.
‘I am absolutely grateful to a number of my students and collaborators, who contributed to this success,’ he said.
You may also like
Drug Delivery
Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody
The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Research & Development
FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design
The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline
Research & Development
Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive
Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage
Research & Development
Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic
Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform
Research & Development
Early stage clinical trials highlight the convergence of novel therapeutics and enabling technologies
Early stage clinical development is increasingly being shaped by advances in drug discovery and the technologies and manufacturing strategies that enable the safe, precise and scalable delivery of new therapies
Research & Development
Breast cancer is the world’s most studied disease for fifth consecutive year according to analysis from Phesi
The US led global clinical trial activity in 2025 and across all top five indications, with China recording the fastest growth in the number of recruiting clinical trial sites
Research & Development
One in ten Britons are using or interested in using GLP-1s for weight loss, according to new research
GLP-1 use and interest was more prevalent among women, as well as those who reported difficulties with their finances or who had experienced psychological distress within the previous month